{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T01:17:08Z","timestamp":1784510228665,"version":"3.55.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>To compare the change in lesion area over 4 years of follow-up in eyes with neovascular age-related macular degeneration (nAMD) treated with anti-vascular endothelial growth factor (VEGF) agents using either a proactive or a reactive regimen in routine clinical practice.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This was a multicentre, retrospective comparative study. Totally, 202 treatment-na\u00efve nAMD eyes (183 patients) received anti-VEGF therapy according to a proactive (<jats:italic>n<\/jats:italic>\u2009=\u2009105) or reactive (<jats:italic>n<\/jats:italic>\u2009=\u200997) regimen. Eyes were included if they had received anti-VEGF injections for a period of at least 4 years and had baseline fluorescein angiography and annual optical coherence tomography (OCT) imaging. Two masked graders independently delineated the lesion\u2019s margins from serial OCT images and growth rates were calculated.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>At baseline, the mean [SD] lesion area was 7.24 [5.6]\u2009mm<jats:sup>2<\/jats:sup> in the proactive group and 6.33 [4.8]\u2009mm<jats:sup>2<\/jats:sup> in the reactive group respectively (<jats:italic>p<\/jats:italic>\u2009=\u20090.22). After four years of treatment, the mean [SD] lesion area in the proactive group was 5.16 [4.5]\u2009mm<jats:sup>2<\/jats:sup> showing a significant reduction compared to the baseline (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). By contrast, the mean [SD] lesion area kept expanding in the reactive group during the follow-up and was 9.24 [6.0]\u2009mm<jats:sup>2<\/jats:sup> at four years (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). The lesion area at 4 years was significantly influenced by treatment regimen, baseline lesion area, and proportion of visits with active lesions.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Eyes treated using a reactive strategy had an increased lesion area and worse visual outcomes at 4 years. By contrast, the proactive regimen was associated with fewer recurrences of active disease, shrinkage of the lesion area, and better vision at four years.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1038\/s41433-023-02652-3","type":"journal-article","created":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T11:01:52Z","timestamp":1688209312000},"page":"161-167","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Lesion area progression in eyes with neovascular age-related macular degeneration treated using a proactive or a reactive regimen"],"prefix":"10.1038","volume":"38","author":[{"given":"Mariano","family":"Cozzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Monteduro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaele Antonio","family":"Esposito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly L.","family":"Spooner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5646-9359","authenticated-orcid":false,"given":"Samantha","family":"Fraser-Bell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Staurenghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Romano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Airaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew A.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3400-1987","authenticated-orcid":false,"given":"Alessandro","family":"Invernizzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,1]]},"reference":[{"key":"2652_CR1","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.ophtha.2019.11.004","volume":"127","author":"RF Spaide","year":"2020","unstructured":"Spaide RF, Jaffe GJ, Sarraf D, Freund KB, Sadda SR, Staurenghi G, et al. Consensus nomenclature for reporting neovascular age-related macular degeneration data: consensus on neovascular age-related macular degeneration nomenclature study group. Ophthalmology 2020;127:616\u201336.","journal-title":"Ophthalmology"},{"key":"2652_CR2","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S0140-6736(18)31550-2","volume":"392","author":"P Mitchell","year":"2018","unstructured":"Mitchell P, Liew G, Gopinath B, Wong TY. Age-related macular degeneration. Lancet 2018;392:1147\u201359.","journal-title":"Lancet"},{"key":"2652_CR3","doi-asserted-by":"publisher","first-page":"E8242","DOI":"10.3390\/ijms21218242","volume":"21","author":"F Ricci","year":"2020","unstructured":"Ricci F, Bandello F, Navarra P, Staurenghi G, Stumpp M, Zarbin M. Neovascular age-related macular degeneration: therapeutic management and new-upcoming approaches. Int J Mol Sci. 2020;21:E8242.","journal-title":"Int J Mol Sci"},{"key":"2652_CR4","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1056\/NEJMoa054481","volume":"355","author":"PJ Rosenfeld","year":"2006","unstructured":"Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, et al. Ranibizumab for neovascular age-related macular degeneration. N. Engl J Med. 2006;355:1419\u201331.","journal-title":"N. Engl J Med"},{"key":"2652_CR5","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ophtha.2008.10.018","volume":"116","author":"DM Brown","year":"2009","unstructured":"Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T, et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology 2009;116:57\u201365.e5","journal-title":"Ophthalmology"},{"key":"2652_CR6","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ophtha.2017.07.014","volume":"125","author":"R Silva","year":"2018","unstructured":"Silva R, Berta A, Larsen M, Macfadden W, Feller C, Mon\u00e9s J, et al. Treat-and-extend versus monthly regimen in neovascular age-related macular degeneration: results with ranibizumab from the TREND study. Ophthalmology 2018;125:57\u201365.","journal-title":"Ophthalmology"},{"key":"2652_CR7","doi-asserted-by":"crossref","unstructured":"Mitchell P, Holz FG, Hykin P, Midena E, Souied E, Allmeier H, et al. Efficacy and safety of intravitreal aflibercept using a treat-and-extend regimen for neovascular age-related macular degeneration: the Aries study. Retina. 2021;41:1911\u201320.","DOI":"10.1097\/IAE.0000000000003128"},{"key":"2652_CR8","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1097\/IAE.0000000000001142","volume":"36","author":"LN Kim","year":"2016","unstructured":"Kim LN, Mehta H, Barthelmes D, Nguyen V, Gillies MC. Metaanalysis of real-world outcomes of intravitreal ranibizumab for the treatment of neovascular age-related macular degeneration. Retina 2016;36:1418\u201331.","journal-title":"Retina"},{"key":"2652_CR9","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.ajo.2019.10.007","volume":"210","author":"M Gillies","year":"2020","unstructured":"Gillies M, Arnold J, Bhandari S, Essex RW, Young S, Squirrell D, et al. Ten-Year Treatment Outcomes of Neovascular Age-Related Macular Degeneration from Two Regions. Am J Ophthalmol. 2020;210:116\u201324.","journal-title":"Am J Ophthalmol"},{"key":"2652_CR10","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1016\/j.ophtha.2012.04.015","volume":"119","author":"U Chakravarthy","year":"2012","unstructured":"IVAN Study Investigators, Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, et al. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology 2012;119:1399\u2013411.","journal-title":"Ophthalmology"},{"key":"2652_CR11","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1016\/j.ophtha.2016.03.045","volume":"123","author":"MG Maguire","year":"2016","unstructured":"Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group, Maguire MG, Martin DF, Ying G-S, Jaffe GJ, Daniel E, et al. Five-year outcomes with anti-vascular endothelial growth factor treatment of neovascular age-related macular degeneration: the comparison of age-related macular degeneration treatments trials. Ophthalmology 2016;123:1751\u201361.","journal-title":"Ophthalmology"},{"key":"2652_CR12","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1159\/000452929","volume":"236","author":"H Giannakaki-Zimmermann","year":"2016","unstructured":"Giannakaki-Zimmermann H, Ebneter A, Munk MR, Wolf S, Zinkernagel MS. Outcomes when switching from a pro re nata regimen to a treat and extend regimen using aflibercept in neovascular age-related macular degeneration. Ophthalmologica 2016;236:201\u20136.","journal-title":"Ophthalmologica"},{"key":"2652_CR13","first-page":"00149","volume":"S0002-9394","author":"F Romano","year":"2023","unstructured":"Romano F, Cozzi E, Airaldi M, Nassisi M, Viola F, Aretti A, et al. Ten-year incidence of fibrosis and risk factors for its development in neovascular age-related macular degeneration. Am J Ophthalmol. 2023;S0002-9394:00149\u20136.","journal-title":"Am J Ophthalmol"},{"key":"2652_CR14","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1016\/j.ophtha.2020.06.019","volume":"127","author":"KL Spooner","year":"2020","unstructured":"Spooner KL, Fraser-Bell S, Cozzi M, Staurenghi G, Invernizzi A, Monteduro D, et al. Macular atrophy incidence and progression in eyes with neovascular age-related macular degeneration treated with VEGF inhibitors using a treat-and-extend or a pro-re-nata regimen. Four year results of the MANEX study. Ophthalmology 2020;127:1663\u201373.","journal-title":"Ophthalmology"},{"key":"2652_CR15","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1056\/NEJMoa1102673","volume":"364","author":"DF Martin","year":"2011","unstructured":"CATT Research Group, Martin DF, Maguire MG, Ying G, Grunwald JE, Fine SL, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011;364:1897\u2013908.","journal-title":"N Engl J Med"},{"key":"2652_CR16","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1016\/j.ophtha.2012.10.014","volume":"120","author":"BG Busbee","year":"2013","unstructured":"Busbee BG, Ho AC, Brown DM, Heier JS, Su\u00f1er IJ, Li Z, et al. Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology 2013;120:1046\u201356.","journal-title":"Ophthalmology"},{"key":"2652_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.preteyeres.2015.07.007","volume":"50","author":"U Schmidt-Erfurth","year":"2016","unstructured":"Schmidt-Erfurth U, Waldstein SM. A paradigm shift in imaging biomarkers in neovascular age-related macular degeneration. Prog Retin Eye Res. 2016;50:1\u201324.","journal-title":"Prog Retin Eye Res"},{"key":"2652_CR18","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1097\/IAE.0000000000000488","volume":"35","author":"A Nagiel","year":"2015","unstructured":"Nagiel A, Sarraf D, Sadda SR, Spaide RF, Jung JJ, Bhavsar KV, et al. Type 3 neovascularization: evolution, association with pigment epithelial detachment, and treatment response as revealed by spectral domain optical coherence tomography. Retina 2015;35:638\u201347.","journal-title":"Retina"},{"key":"2652_CR19","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/j.ajo.2015.06.030","volume":"160","author":"L Kuehlewein","year":"2015","unstructured":"Kuehlewein L, Bansal M, Lenis TL, Iafe NA, Sadda SR, Bonini Filho MA, et al. Optical coherence tomography angiography of type 1 neovascularization in age-related macular degeneration. Am J Ophthalmol. 2015;160:739\u2013748.e2","journal-title":"Am J Ophthalmol"},{"key":"2652_CR20","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1111\/aos.13364","volume":"95","author":"F Sulzbacher","year":"2017","unstructured":"Sulzbacher F, Pollreisz A, Kaider A, Kickinger S, Sacu S, Schmidt-Erfurth U, et al. Identification and clinical role of choroidal neovascularization characteristics based on optical coherence tomography angiography. Acta Ophthalmol. 2017;95:414\u201320.","journal-title":"Acta Ophthalmol"},{"key":"2652_CR21","doi-asserted-by":"crossref","unstructured":"Choi M, Kim S-W, Yun C, Oh J-H, Oh J. Predictive role of optical coherence tomography angiography for exudation recurrence in patients with type 1 neovascular age-related macular degeneration treated with pro-re-nata protocol. Eye (Lond). 2022;37:34\u201341.","DOI":"10.1038\/s41433-021-01879-2"},{"key":"2652_CR22","first-page":"3751702","volume":"2018","author":"A Miere","year":"2018","unstructured":"Miere A, Oubraham H, Amoroso F, Butori P, Astroz P, Semoun O, et al. Optical coherence tomography angiography to distinguish changes of choroidal neovascularization after anti-VEGF therapy: monthly loading dose versus pro re nata regimen. J Ophthalmol. 2018;2018:3751702.","journal-title":"J Ophthalmol"},{"key":"2652_CR23","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.ajo.2017.12.005","volume":"187","author":"D Xu","year":"2018","unstructured":"Xu D, D\u00e1vila JP, Rahimi M, Rebhun CB, Alibhai AY, Waheed NK, et al. Long-term progression of type 1 neovascularization in age-related macular degeneration using optical coherence tomography angiography. Am J Ophthalmol. 2018;187:10\u201320.","journal-title":"Am J Ophthalmol"},{"key":"2652_CR24","doi-asserted-by":"publisher","first-page":"4501395","DOI":"10.1155\/2020\/4501395","volume":"2020","author":"M Rispoli","year":"2020","unstructured":"Rispoli M, Savastano MC, Lumbroso B, Toto L, Di Antonio L. Type 1 choroidal neovascularization evolution by optical coherence tomography angiography: long-term follow-up. Biomed Res Int. 2020;2020:4501395.","journal-title":"Biomed Res Int"},{"key":"2652_CR25","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.preteyeres.2017.12.002","volume":"65","author":"H Mehta","year":"2018","unstructured":"Mehta H, Tufail A, Daien V, Lee AY, Nguyen V, Ozturk M, et al. Real-world outcomes in patients with neovascular age-related macular degeneration treated with intravitreal vascular endothelial growth factor inhibitors. Prog Retin Eye Res. 2018;65:127\u201346.","journal-title":"Prog Retin Eye Res"},{"key":"2652_CR26","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.ophtha.2018.08.035","volume":"126","author":"GJ Jaffe","year":"2019","unstructured":"Jaffe GJ, Ying G-S, Toth CA, Daniel E, Grunwald JE, Martin DF, et al. Macular morphology and visual acuity in year five of the comparison of age-related macular degeneration treatments trials. Ophthalmology 2019;126:252\u201360.","journal-title":"Ophthalmology"},{"key":"2652_CR27","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.oret.2019.05.017","volume":"4","author":"TA Ciulla","year":"2020","unstructured":"Ciulla TA, Hussain RM, Pollack JS, Williams DF. Visual acuity outcomes and anti-vascular endothelial growth factor therapy intensity in neovascular age-related macular degeneration patients: a real-world analysis of 49\u2009485 eyes. Ophthalmol Retin. 2020;4:19\u201330.","journal-title":"Ophthalmol Retin"},{"key":"2652_CR28","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1097\/IAE.0000000000002668","volume":"40","author":"MR Starr","year":"2020","unstructured":"Starr MR, Kung FF, Mejia CA, Bui YT, Bakri SJ. Ten-year follow-up of patients with exudative age-related macular degeneration treated with intravitreal anti-vascular endothelial growth factor injections. Retina 2020;40:1665\u201372.","journal-title":"Retina"},{"key":"2652_CR29","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1016\/j.ophtha.2019.11.010","volume":"127","author":"SR Sadda","year":"2020","unstructured":"Sadda SR, Guymer R, Mon\u00e9s JM, Tufail A, Jaffe GJ. Anti-vascular endothelial growth factor use and atrophy in neovascular age-related macular degeneration: systematic literature review and expert opinion. Ophthalmology 2020;127:648\u201359.","journal-title":"Ophthalmology"},{"key":"2652_CR30","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1097\/IAE.0000000000002779","volume":"40","author":"KYC Teo","year":"2020","unstructured":"Teo KYC, Joe AW, Nguyen V, Invernizzi A, Arnold JJ, Barthelmes D, et al. Prevalence and risk factors for the development of physician-graded subretinal fibrosis in eyes treated for neovascular age-related macular degeneration. Retina 2020;40:2285\u201395.","journal-title":"Retina"},{"key":"2652_CR31","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1001\/jamaophthalmol.2020.3001","volume":"138","author":"RN Evans","year":"2020","unstructured":"Evans RN, Reeves BC, Maguire MG, Martin DF, Muldrew A, Peto T, et al. Associations of variation in retinal thickness with visual acuity and anatomic outcomes in eyes with neovascular age-related macular degeneration lesions treated with anti-vascular endothelial growth factor agents. JAMA Ophthalmol. 2020;138:1043\u201351.","journal-title":"JAMA Ophthalmol"},{"key":"2652_CR32","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/j.oret.2020.09.019","volume":"5","author":"K Spooner","year":"2021","unstructured":"Spooner K, Fraser-Bell S, Hong T, Phan L, Wong JG, Chang A. Long-term anti-vascular endothelial growth factor treatment for neovascular age-related macular degeneration: the LATAR study: report 1: ten-year, real-world outcomes. Ophthalmol Retin. 2021;5:511\u20138.","journal-title":"Ophthalmol Retin"},{"key":"2652_CR33","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1136\/bjophthalmol-2014-305327","volume":"99","author":"FG Holz","year":"2015","unstructured":"Holz FG, Tadayoni R, Beatty S, Berger A, Cereda MG, Cortez R, et al. Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration. Br J Ophthalmol. 2015;99:220\u20136.","journal-title":"Br J Ophthalmol"}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41433-023-02652-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-023-02652-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-023-02652-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T05:04:30Z","timestamp":1704344670000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41433-023-02652-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,1]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["2652"],"URL":"https:\/\/doi.org\/10.1038\/s41433-023-02652-3","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,1]]},"assertion":[{"value":"17 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}